Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
Cumberland Pharmaceuticals reported top-line results from its 12-month Phase 2a ASSIST-SSc trial of oral ifetroban in systemic sclerosis, with the drug generally well tolerated and no serious adverse events deemed related to study drug. The trial enrolled 41 subjects (31 ifetroban, 10 placebo) and was not powered for efficacy; limited disease progression in both groups reduced the ability to detect a treatment difference, and the company states efficacy conclusions cannot be drawn.
Key figures
- Drug Name
- ifetroban
- Phase Of Trial
- Phase 2a
- Trial name
- ASSIST-SSc
- Trial duration
- 12-month
- Us ssc patients
- 100000
- Subjects placebo
- 10
- Subjects ifetroban
- 31
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.